Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific CD4 down-modulating compounds with potent anti-HIV activity.

Kurt Vermeire1, Dominique Schols

  • 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.

Journal of Leukocyte Biology
|September 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Plasticizer Polarity on the Permeability of Hydroxypropyl Methylcellulose Phthalate Films.

Molecular pharmaceutics·2026
Same author

The development of biologically contained Sudan virus as an alternative and safe tool for fundamental filovirus research.

Emerging microbes & infections·2026
Same author

Discovery of 1-(3-phenoxybenzyl)-4-(1-phenyl-1H-1,2,3-triazol-4-yl)piperidine analogues as potent and selective agonists of the human CC chemokine receptor 8.

European journal of medicinal chemistry·2026
Same author

Integrated omics reveal a unique antibacterial mechanism of action for the small molecule HSI#6.

Current research in microbial sciences·2026
Same author

High-Affinity Nanobody Against the LEDGF PWWP Domain Inhibits Chromatin Binding In Vitro.

Biomolecules·2026
Same author

Membrane-Permeable Nucleoside T-1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same journal

Correction to: IL-27 signaling negatively regulates FcɛRI-mediated mast cell activation and allergic response.

Journal of leukocyte biology·2026
Same journal

Autofluorescence enables detection and quantification of EETosis in human leukocyte cultures.

Journal of leukocyte biology·2026
Same journal

Cold Atmospheric Plasma as an Immunomodulator: Suppression of T-cell Hyperactivation and Graft-versus-Host Disease via Redox Regulation.

Journal of leukocyte biology·2026
Same journal

Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis.

Journal of leukocyte biology·2026
Same journal

Eosinophil Essentials: Identification and Assessment of Activity.

Journal of leukocyte biology·2026
Same journal

Immune cell landscape reveals 5 immune-related subtypes and molecular characteristics with prognostic and therapeutic implications in pan-cancer.

Journal of leukocyte biology·2026
See all related articles

New anti-HIV drugs targeting viral entry are crucial for combating AIDS. This review highlights agents blocking HIV-1 attachment, coreceptor interaction, and fusion, including novel compounds modulating CD4 receptors.

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • Acquired Immunodeficiency Syndrome (AIDS) remains a global health challenge requiring novel therapeutic strategies.
  • Current anti-human immunodeficiency virus (HIV) drugs necessitate the development of new antiviral classes.
  • Understanding HIV-1 entry is key for designing effective interventions.

Purpose of the Study:

  • To review current therapeutic agents targeting HIV-1 entry.
  • To highlight novel approaches in anti-HIV drug development.
  • To emphasize the potential of entry inhibitors in combating AIDS.

Main Methods:

  • Review of existing literature on HIV-1 entry inhibitors.
  • Analysis of agents targeting viral attachment, coreceptor binding, and fusion.

Related Experiment Videos

  • Discussion of specific compounds like PRO 542, PRO 2000, CV-N, SCH-C, and AMD3100.
  • Highlighting cyclotriazadisulfonamides as a novel class of CD4 receptor modulators.

    • Main Results:

    • Several therapeutic agents effectively inhibit HIV-1 entry by targeting gp120-CD4 binding or coreceptor interactions (CCR5, CXCR4).
    • Cyclotriazadisulfonamides demonstrate unique anti-HIV activity by down-modulating CD4 receptors on immune cells.
    • The success of T-20, an approved entry inhibitor, supports further development in this area.

    Conclusions:

    • Targeting HIV-1 entry represents a promising strategy for developing new antiretroviral therapies.
    • Novel compounds, such as cyclotriazadisulfonamides, offer unique mechanisms for inhibiting HIV replication.
    • Continued research into entry inhibitors is essential for advancing AIDS treatment and prevention.